Roles of Uremic Toxins in Uremic Sacropenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03060590|
Recruitment Status : Completed
First Posted : February 23, 2017
Last Update Posted : March 11, 2020
Background. In advanced chronic kidney disease (CKD), multiple metabolic and nutritional abnormalities may contribute to the impairment of skeletal muscle mass and function thus predisposing patients to the condition of sarcopenia. Herein, we aim to investigate the association of uremic toxins and sacropenia. In addition, the prevalence and mortality predictive power of sarcopenia, defined by different methods, in a cohort of hemodialysis patients.
Methods. We plan to evaluate 300 HD patients. Sarcopenia was defined as reduced muscle function assessed by handgrip strength (HGS <30th percentile of a population-based reference adjusted for sex and age) plus diminished muscle mass assessed by different methods: (i) midarm muscle circumference (MAMC) <90% of reference value (A), (ii) muscle wasting by DEXA (B) and (iii) reduced skeletal muscle mass index (<10.76 kg/m² men; <6.76 kg/m² women) estimated by bioelectrical impedance analysis (BIA) (C). Serum levels of 3 established uremic toxins such as indoxyl sulfate, p-cresol and hippuric acid will be measured. Besides, various relevant inflammatory markers will also be assessed. Patients will be followed for up to 3 years for all-cause mortality.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||111 participants|
|Official Title:||Association of Uremic Toxins and Sacropenia in Hemodialysis Patients|
|Actual Study Start Date :||April 1, 2017|
|Actual Primary Completion Date :||December 31, 2018|
|Actual Study Completion Date :||January 31, 2020|
- Presence of Sarcopenia [ Time Frame: 3 years ]To evaluate the association of sacropenia defined according to 1. Low muscle mass 2. Low muscle strength 3. Low physical performance and serum levels of some uremic toxins such as indoxyl sulfate, p-cresol and hippuric acid will be measured.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03060590
|Tungs' Taichung MetroHarbour Hospital|
|Principal Investigator:||Paik Seong Lim, PhD||Tungs' Taichung Metroharbour Hospital|